BioAge Labs, Inc. stock analysis
Want to see BIOA full AI Analyst Report?
BioAge Labs, Inc. (BIOA) Stock Price & Analysis
BIOA Stock Chart & Stats
- Day’s Range
- $5.08 - $5.67
- 52-Week Range
- $4.81 - $25.96
- Previous Close
- $5.55
- Volume
- N/A
- Average Volume (3M)
- 819.79K
- Market Cap
- $239.90M
- Enterprise Value
- $44.61M
- Total Cash (Recent Filing)
- $283.64M
- Total Debt (Recent Filing)
- $2.73M
- Price to Earnings (P/E)
- ―
- Beta
- 1.85
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- -0.74
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage gives BioAge financial flexibility while it advances clinical programs and absorbs operating losses. The limited debt burden reduces refinancing pressure and preserves more strategic options than a similarly unprofitable biotech carrying substantial borrowings.
Clinical Pipeline Progress
Progressing BGE-102 into Phase 2 creates a more developed clinical asset and provides defined milestones for assessing efficacy in diabetic macular edema. The trial may also guide expansion into other NLRP3-driven retinal diseases, supporting broader pipeline value.
BGE-102 Differentiation
The reported pharmacologic activity, tolerability, and tissue penetration support a potentially differentiated profile for BGE-102. A once-daily oral approach addressing several inflammatory pathways could broaden its usefulness if later-stage studies confirm these early findings.
Bears Say
Heavy Cash Burn
Deeply negative operating and free cash flow indicate that BioAge is not yet funding its activities internally. Continued clinical investment therefore depends on its existing resources or external financing, creating pressure to improve operating losses before cash consumption materially weakens flexibility.
Persistent Large Losses
Repeated and widening losses show that profitability remains distant and that the business is still consuming capital to support development. If this pattern continues, cumulative losses can erode the equity base and reduce the resources available for advancing multiple programs.
Weak Revenue Base
A small and declining revenue base provides limited support for BioAge’s substantial research and development spending. Although gross profit is high, operating expenses overwhelm it, leaving the company dependent on financing and future clinical success rather than current commercial earnings.
BioAge Labs, Inc. News
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
Citi analyst Samantha Semenkow has maintained their bullish stance on BIOA stock, giving a Buy rating on September 14. Samantha Semenkow has given his Buy rating due to a combination
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
What is BioAge Labs, Inc.’s market cap?
When is BioAge Labs, Inc.’s upcoming earnings report date?
How were BioAge Labs, Inc.’s earnings last quarter?
Is BioAge Labs, Inc. overvalued?
Does BioAge Labs, Inc. pay dividends?
What is BioAge Labs, Inc.’s EPS estimate?
How many shares outstanding does BioAge Labs, Inc. have?
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
What is the TipRanks Smart Score and how is it calculated?
BioAge Labs, Inc. Stock Smart Score
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Kristen Fortney
- Employees
- 61
- Website
- bioagelabs.com
- Address
- 5885 Hollis Street, Emeryville, CA, 94608, US
BioAge Labs, Inc. (BIOA) Earnings & Revenues
BIOA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |









